Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib trial to determine Givastomig in newly diagnosed (frontline treatment) gastric cancer and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor

Next Previous
Trial Profile

A phase Ib trial to determine Givastomig in newly diagnosed (frontline treatment) gastric cancer and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givastomig (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Biliary cancer; Gastric cancer; Oesophageal cancer; Pancreatic ductal carcinoma
  • Focus Therapeutic Use
  • Sponsors NovaBridge Biosciences

Most Recent Events

  • 18 Feb 2026 Results presented in the NovaBridge Biosciences Media Release.
  • 18 Feb 2026 According to a NovaBridge Biosciences media release, updated results from the Phase 1b dose expansion part of this study will be presented at a major medical conference in 2H 2026.
  • 29 Oct 2025 According to NovaBridge Biosciences media release, I-MAB Biopharma has changed its name to NovaBridge Biosciences.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top